SCHEMBL279233

SCHEMBL279233

CC(C)(C)OC(=O)N1CC[C@H](Oc2ccc(Cl)cc2C=O)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 3/20 0.49
PIK3CD O00329 4/20 0.49
PIK3CA P42336 2/20 0.49
PIK3CB P42338 2/20 0.49
PIK3CG P48736 2/20 0.49
PDE4D Q08499 3/20 0.46
PDE4A P27815 2/20 0.46
PDE4C Q08493 2/20 0.46
GPR119 Q8TDV5 1/20 0.45
CACNB4 O00305 2/20 0.43
CACNA1A O00555 2/20 0.43
CACNA1G O43497 2/20 0.43
CACNG3 O60359 2/20 0.43
CACNA1F O60840 2/20 0.43
CACNA1H O95180 2/20 0.43
CACNB3 P54284 2/20 0.43
CACNA2D1 P54289 2/20 0.43
CACNG7 P62955 2/20 0.43
CACNA1B Q00975 2/20 0.43
CACNA1D Q01668 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274926 1.00 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL274927 1.00 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2420719 0.94 PDE4B (0.52) PDE4BPDE4DPDE4APDE4CGPR119
SCHEMBL279184 0.87 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL12437491 0.87 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3400187 0.87 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL278899 0.87 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3400190 0.87 PDE4B (0.49) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL2280531 0.86 PDE4B (0.52) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL3100304 0.85 RBP4 (0.59) PDE4BPIK3CDPIK3CAPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134001-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2012-03-13 US disclosed
EP-2229396-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-10 EP disclosed
EP-2229396-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2010-09-22 EP disclosed
WO-2009077357-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 WO disclosed
US-20090156610-A1 Spiroindolinone Derivatives DING QINGJIE 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156610-A1 Spiroindolinone Derivatives SDHA, AR, XPOT PDE4B 3594/4885PIK3CD 3156/4885PIK3CA 1833/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.